Manufacture of propranolol 3% gel and comparing it with placebo in the prevention of radiotherapy induced dermatitis in breast cancer patients

Manufacture of propranolol 3% gel and comparing it with placebo in the prevention of radiotherapy induced dermatitis in breast cancer patients; A double-blind clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190425043368N4

Enrollment

Registered

2026-05-23

Start date

2026-05-24

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Radiotherapy induced dermatitis. Acute radiodermatitis

Interventions

Intervention 1: Intervention group: Recipient of 3% Propranolol Gel. Propranolol hydrochloride powder was obtained from Daroupakhsh Pharmaceutical Chemical Company and the gels are made weekly in the

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Pathological diagnosis of breast cancer Patients who have not had their entire breast removed Radiotherapy recipient with a maximum dose of 60 Gy in 200 cGy fractions

Exclusion criteria

Exclusion criteria: People with known allergies or contraindications to beta-blockers Unwillingness to sign the consent form Inflammatory metastatic carcinoma Concomitant use of other antioxidant drugs Connective tissue diseases or chronic skin disease

Design outcomes

Primary

Measure	Time frame
Acute radiation dermatitis (ARD) grade. Timepoint: Weekly for up to 6 weeks. Method of measurement: Based on Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) and Common Terminology Criteria for Adverse Events (CTCAE) version 5.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahtabalsadat Mirjalili

Yazd University of Medical Sciences

Mahtab.mirjalili@gmail.com+98 35 3820 3419

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026